CD70 and renal cell adenocarcinoma: A phase I/II clinical trial evaluating the efficacy of CD70-targeted CAR T cells containing the truncated form of CD27 and the intracellular costimulatory domain of 4-1BB in patients with CD70+ pancreatic cancer, renal cell cancer, breast cancer, melanoma, and ovarian cancer has been initiated, but is currently suspended (NCT02830724).